Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research report sent to investors on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Performance

Shares of NASDAQ SRNE opened at $0.01 on Monday. Sorrento Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.42. The stock has a 50 day moving average price of $0.02 and a 200 day moving average price of $0.05.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.